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Abstract
Purpose To evaluate the safety and tolerability of IgPro20 manual push (also known as rapid push) infusions at flow rates of 0.5–
2.0 mL/min.
Methods Patients with primary immunodeficiency (PID) with previous experience administering IgPro20 (Hizentra®, CSL
Behring, King of Prussia, PA, USA) were enrolled in the Hizentra® Label Optimization (HILO) study (NCT03033745) and
assigned to Pump-assisted Volume Cohort, Pump-assisted Flow Rate Cohort, or Manual Push Flow Rate Cohort; this report
describes the latter. Patients administered IgPro20 via manual push at 0.5, 1.0, and 2.0 mL/min/site for 4 weeks each. Responder
rates (percentage of patients who completed a predefined minimum number of infusions), safety outcomes, and serum immunoglobulin G (IgG) trough levels were evaluated.
Results Sixteen patients were treated; 2 patients (12.5%) discontinued at the 1.0-mL/min level (unrelated to treatment). Responder
rates were 100%, 100%, and 87.5% at 0.5-, 1.0-, and 2.0-mL/min flow rates, respectively. Mean weekly infusion duration decreased
from 103–108 to 23–28 min at the 0.5- and 2.0-mL/min flow rates, respectively. Rates of treatment-related treatment-emergent
adverse events (TEAEs) per infusion were 0.023, 0.082, and 0.025 for the 0.5-, 1.0-, and 2.0-mL/min flow rates, respectively. Most
TEAEs were mild local reactions and tolerability (infusions without severe local reactions/total infusions) was 100% across flow rate
levels. Serum IgG levels (mean [SD]) were similar at study start (9.36 [2.53] g/L) and end (9.58 [2.12] g/L).
Conclusions Subcutaneous IgPro20 manual push infusions at flow rates up to 2.0 mL/min were well tolerated and reduced
infusion time in treatment-experienced patients with PID.
Trial Registration NCT03033745
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Introduction
Primary immunodeficiency (PID) diseases, such as common
variable immune deficiency (CVID) and X-linked agammaglobulinemia (XLA), are characterized by defective antibody
production, such that patients require lifelong immunoglobulin G (IgG) replacement therapy to help prevent infections [1].
PID in children and adults is treated with either intravenous
IgG or subcutaneous IgG (SCIG) [1, 2]. One of the primary
benefits of SCIG is the flexibility and convenience it offers
patients, as it can be self-administered at home and at varying
dosing intervals to suit patients’ schedules [2–5].
SCIG has conventionally been administered using infusion
pumps, but more recently manual push (also known as rapid
push) administration using a syringe and butterfly needle has
emerged as an alternative method [6–8]. Infusions of 20%
SCIG products generally deliver up to 25 mL per injection
site, depending on patient age and weight. Two currently
available products may be infused at volumes higher than
25 mL: Cuvitru® (SCIG [human] 20%, Takeda, Tokyo,
Japan) at volumes of up to 60 mL per injection site [9], and
Gammagard Liquid® (SCIG [human] 10%, Takeda, Tokyo,
Japan) at volumes of up to 30 mL per injection site [10]. Both
pump and manual push administrations of SCIG have distinct
advantages. Pump-assisted infusion time for an average weekly SCIG dose is generally 1–2 h whereas manual push infusion can be performed in 5–20 min [1, 6, 7, 11, 12]. Manual
push SCIG administration allows shorter infusion times,
allows simple infusions without the need for an infusion
pump, and confers flexibility, as the patient can “push”
SCIG at a rate with which they are comfortable [6, 12].
Pump-assisted infusions generally allow infusions of larger
volumes and thus require fewer needle sticks and less frequent
infusions than manual push [13].
IgPro20 (Hizentra®, CSL Behring, King of Prussia, PA,
USA) is a ready-to-use 20% formulation of polyvalent SCIG
approved since 2010 for the treatment of patients with PID
aged ≥ 2 years [14, 15]. In the United States of America
(USA), the approved infusion parameters for IgPro20 in patients with PID via pump-assisted infusion are a volume up to
25 mL per injection site and a flow rate up to 25 mL/h per
injection site [14]. The European Union (EU) approved parameters for pump-assisted infusion of IgPro20 permit infusion at slightly higher rates than in the USA [15]. Furthermore,
the EU has approved parameters for manual push infusion of
IgPro20 up to 2.0 mL/min/site if patients tolerate initial loading doses at a rate of 0.5 mL/min/site [15]. Higher infusion
flow rates allow for shorter infusion times, which is preferred
by patients and caregivers [8, 16–18]. Infusion flow rates >
25 mL/h for 20% SCIG products have been investigated for

both methods of SCIG administration but have not been systematically evaluated and compared [19–25]. Two studies
have shown that 20% SCIG manual push infusion flow rates
≥ 60 mL/h/site are well tolerated in pediatric and adult patients
[22, 25].
Although manual push infusions of SCIG products, including IgPro20, have been reported in clinical practice [6, 7, 11,
16, 22, 25], this administration method has not been rigorously assessed in prospective clinical trials and is not approved by
the US Food and Drug Administration for IgPro20.
Furthermore, no studies to date have prospectively evaluated
increasing infusion parameters (i.e., flow rates, volumes) for
20% SCIG products using either pump-assisted or manual
push administration methods. The Hizentra ® Label
Optimization (HILO) study was designed to evaluate the safety and tolerability of higher infusion parameters than currently
approved for pump-assisted infusions of IgPro20 and of increasing flow rates for manual push administration of
IgPro20. The overall study design and the results of the
pump-assisted cohorts are reported in the accompanying manuscript [26]. This report presents findings from the Manual
Push Flow Rate Cohort with regard to the safety and tolerability of IgPro20 infusion using flow rates in the range of 0.5–
2.0 mL/min (30–120 mL/h) per injection site.

Methods
Patients
Patients who were receiving a stable dose of IgPro20 therapy
at a flow rate of ~ 0.5 mL/min per injection site for ≥ 1 month
prior to study day 1 were included in the Manual Push Flow
Rate Cohort. Three flow rate levels were tested for 4 weeks
each, over a total duration of 12 weeks: 0.5 mL/min, 1.0 mL/
min, and 2.0 mL/min. IgPro20 infusions were administered 2–
7 times per week; the frequency of infusions remained the
same throughout the study for each individual patient.
Average flow rates per manual push infusion were estimated
by dividing infused volume by infusion time, as it is not possible to perform manual push at a constant rate. Patients kept
records for all infusions in electronic diaries (eDiaries) or
backup paper diaries.
Manual push administration was performed using a 10-mL
or 20-mL syringe and a short length of tubing with a butterfly
needle. IgPro20 was delivered by several short syringe plunger pushes with short breaks in between. Because it is impossible to perform manual push at a constant rate, average flow
rates per infusion were estimated by dividing the volume infused in milliliters by the infusion duration in minutes. The
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eDiary and paper instruction forms provided exact recommendations of individual dose and infusion duration depending on
the actual volume infused in order to achieve the target flow
rates of 0.5, 1.0, and 2.0 mL/min for every patient.
Responders for each flow rate level were defined as
patients who administered the minimum prespecified number of valid infusions for a given infusion parameter level,
as specified in Table S1. An infusion was considered valid
in the Manual Push Flow Rate Cohort if a patient completed ≥ 95% of the planned infusion volume administered in a
given day, with an infusion duration not longer than 10%
of the calculated infusion duration (or 1 min, whichever
was higher).

Safety Assessments
Responder Analysis
The primary study endpoint was the responder rate for each
IgPro20 manual push infusion flow rate. The responder rate
was defined as the number of responders at a given flow rate
level out of all patients in the Manual Push Flow Rate Cohort
who received ≥ 1 IgPro20 dose, expressed as a percentage. A
flow rate level was considered successful if the responder rate
was ≥ 33%. The threshold of ≥ 33% was based on our analysis
of previous IgPro20 clinical studies and consultations with
physicians in the field of PID. Responder analyses were stratified by patient age (≤ 17 years, > 17 years) and BMI (nonobese, < 30 kg/m2; obese, ≥ 30 kg/m2).

Safety and Tolerability
Secondary endpoints included the safety and tolerability of
IgPro20 infusion parameters. Adverse events (AEs) starting
on or after the date of the first in-study IgPro20 administration
were considered treatment-emergent AEs (TEAEs). TEAEs
were characterized in detail using data up to a patient’s nonresponse at a specific flow rate. Safety data after non-response
were also collected but excluded from analyses of TEAEs
carried out under forced upward titration conditions.
Tolerability was defined as the number of infusions without
severe local reactions per the total number of infusions, irrespective of infusion validity.

J Clin Immunol (2021) 41:66–75

Statistical Analysis
Continuous variables were summarized by mean, standard
deviation (SD), median, minimum, and maximum; categorical
variables were summarized as frequencies and percentages.
Percentages were based on non-missing values. Data points
following a patient’s non-response (i.e., inability to administer
the prespecified minimum number of valid infusions at a given parameter level during 4 weeks at that level) were excluded
from these analyses, as infusions administered after nonresponse were not considered to be administered under forced
upward titration. Analyses were performed on the safety analysis set, which included all patients who were enrolled in the
study and received ≥ 1 dose or a partial dose of IgPro20 during
the study. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Overall infusion compliance was determined based on patient diaries of administered infusions and calculated as a percentage:
Overall compliance ð%Þ
¼

100  Cumulative actual dose over all infusions
Cumulative planned dose over all infusions

Results
Patient Disposition and Demographics
Overall, 16 patients were enrolled in the Manual Push Flow
Rate Cohort, 14 of whom completed the study (Fig. 1). Two
Patients screened
(screened analysis set): N=55

Screening failures: N=6

Patients enrolled: N=49

Patients who received treatment
(safety analysis set): N=49
Pump Cohorts: N=33
Manual Push Flow Rate Cohort: N=16

Efficacy Assessments
Due to the relatively short duration of the study per patient, no
clinical efficacy variables were assessed. However, serum IgG
trough levels were assessed at baseline (day 1) and end of
study as a surrogate efficacy parameter.

Discontinued: N=2
Adverse event: n=1
Protocol deviation: n=1

Completed: N=14

Fig. 1 Patient disposition. Disposition of patients in the HILO study with
a focus on the Manual Push Flow Rate Cohort
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Table 1

Patient demographics and baseline characteristics

Characteristics

Manual Push Flow Rate Cohort,
N = 16

Other immunodeficiency category includes secondary antibody deficiency (protocol violation) and specific antibody deficiency with normal
IgG concentration and normal number of B cells
BMI, body mass index; IgG, immunoglobulin G; PID, primary immunodeficiency; SD, standard deviation

Age (years)
Mean (SD)

47.9 (13.3)

Median (min, max)
Age category (years), n (%)
≤ 17

49.5 (17, 65)

> 17
Sex, n (%)

15 (93.8)

Female
Male

10 (62.5)
6 (37.5)

Race, n (%)
White

12 (75.0)

1 (6.3)

Black/African American
Other

1 (6.3)
1 (6.3)

Multiple

2 (12.5)

Body weight (kg)
Mean (SD)
Median (min, max)
BMI (kg/m2)
Median (min, max)

81.8 (15.7)

patients (12.5%) discontinued the study at the 1.0-mL/min
infusion level; one discontinuation was due to an AE (suicide
attempt, unrelated to study drug), and the other was due to a
protocol deviation (violation of one of the inclusion criteria:
diagnosis of secondary immunodeficiency).
The patient demographics and clinical characteristics of
the Manual Push Flow Rate Cohort are presented in
Table 1. Mean age was 47.9 years; 15 patients (93.8%)
were aged ≥ 18 to ≤ 65 years, and 1 patient (6.3%) was
aged 17 years (Table 1). The mean body weight was
81.8 kg. BMI ranged from 19.2 to 40.0 kg/m2, and 7
patients (43.8%) were considered obese (BMI ≥ 30 kg/
m2). At study entry, individual patients’ IgPro20 infusion
frequency ranged from 2 to 7 infusions per week with
volumes of 5–40 mL per infusion.

81.1 (52.3, 107.0)
26.7 (19.2, 40.0)

Responder Analysis

BMI category, n (%)
9 (56.3)
< 30 kg/m2
7 (43.8)
≥ 30 kg/m2
Concomitant diseases (≥ 4 patients), n (%)
Any concomitant disease

16 (100.0)

Asthma

8 (50.0)

Chronic sinusitis

7 (43.8)

Gastroesophageal reflux disease

6 (37.5)

Depression

6 (37.5)

Bronchiectasis

4 (25.0)

Urinary tract infection
Hypothyroidism

4 (25.0)
4 (25.0)

Hypertension

4 (25.0)

Immunodeficiency disease, n (%)
Common variable
14 (87.5)
immunodeficiency disease
2 (12.5)
Other immunodeficiencya
Time since first PID diagnosis (years)
Mean (SD)

12.5 (13.8)

Median (min, max)

4.8 (0.1, 46.0)

The percentage of responders at 0.5-, 1.0-, and 2.0-mL/min
flow rates was 100%, 100%, and 87.5%, respectively, meeting
the prespecified success criterion ≥ 33% for all infusion parameter levels (Fig. 2). The two patients who discontinued at
the 1.0-mL/min flow rate met responder criteria for this flow
rate. All 14 patients who reached the 2.0-mL/min flow rate
were responders at this level. The percentage of valid infusions before non-response was 99.5%, 100%, and 98.5% for
the 0.5-, 1.0-, and 2.0-mL/min flow rates, respectively.
For each flow rate level, there were no clinically meaningful differences in the percentage of responders between nonobese and obese patients. Responder rates in obese patients
were 100% for all flow rates. In non-obese patients, responder
rates were 100% except at the 2.0-mL/min flow rate, which
had a 77.8% responder rate due to the 2 patients who
discontinued early at the 1.0-mL/min flow rate.

Effect of High Flow Rates on Infusion Time

IgG levels at time of first PID diagnosis (g/L)
n

9

Mean (SD)

2.7 (2.1)

Median (min, max)

2.6 (0.1, 6.6)

Prestudy IgG trough levels (g/L)
n

15

Mean (SD)

9.1 (1.9)

Median (min, max)

9.1 (5.7, 13.3)

The mean weekly duration of infusions decreased over time
with increasing infusion flow rates (Fig. 3). At the 0.5-mL/min
rate, the mean (SD) weekly infusion time ranged from 103
(31.4) to 108 (31.2) min during weeks 1–4, which decreased
to 52 (16.9) to 55 (12.9) min at the 1.0-mL/min rate during
weeks 5–8, and to 23 (9.8) to 28 (7.8) min at the 2.0-mL/min
level during weeks 9–12.

70
100
90
80
70
Responders, %

Fig. 2 Responder analysis of
increasing manual push flow rates
(safety analysis set). Responders
were patients who achieved the
prespecified minimum of valid
infusions at a certain level. The
percentage of responders at each
flow rate is based on all patients in
the Manual Push Flow Rate
Cohort (n = 16). The prespecified
success criterion was a responder
rate of ≥ 33% for each flow rate
(dashed line). Non-responders
were patients who did not meet
the minimum number of valid
infusions at a given flow rate
during the 4 weeks planned for
that flow rate. The number of
responders for each flow rate is
shown at the bottom of each bar
(underlined). aBefore the start
date of non-response
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100
87.5

60
50

≥33% prespecified
success criterion

40
30
20

16/16

16/16

14/16

1.0

2.0

10
0
0.5

Flow rate, mL/min/site

Number of patients with ≥1 infusiona

16

16

14

Number of infusions before non-response

220

208

198

219 (99.5)

208 (100)

195 (98.5)

Number (%) of valid infusions

Infusion Compliance
Overall infusion compliance (cumulative actual dose
administered/cumulative planned dose) was high for all manual push flow rates, with most patients achieving ≥ 90% compliance (Table 2). In 5 patients, compliance was < 90% at the
0.5- and 1.0-mL/min rates. Two of these patients had missing
data records for some infusions at the 0.5-mL/min rate
resulting in compliance < 90%. One patient received fewer
infusions than planned at the 1.0-mL/min rate to compensate
for a higher number of infusions administered at the previous
infusion parameter level. Two patients missed doses at the
1.0-mL/min level, because of a natural disaster (n = 1) and
for an unknown reason (n = 1). One patient discontinued owing to an unrelated serious AE (suicide attempt) after receiving
5 of 8 planned infusions at the 1.0-mL/min rate. The compliance < 90% at the 0.5- and 1.0-mL/min flow rates did not

translate to non-response, as these patients still administered
the prespecified minimum number of valid infusions for those
flow rates.

Safety and Tolerability
The mean weekly IgPro20 dose administered ranged from 113
to 137 mg/kg over the study duration. Both mean and median
IgPro20 volumes and doses were consistent with those
planned. The mean (SD) weekly volume (54.9 [15.5] mL)
and dose (137.2 [43.0] mg/kg) of IgPro20 were consistent
with planned values for the cohort (mean [SD]; planned volume, 54.3 [14.6] mL/week; planned dose, 135.7 [40.0] mg/kg/
week). The median volume administered in the cohort was
55.0 mL, and the median dose was 127.3 mg/kg.
Individual median cumulative weekly IgPro20 volumes
administered during the study using manual push ranged from
Flow rate per
injection site
0.5 mL/min
1.0 mL/min
2.0 mL/min

160
140
Duration of infusion, minutes

Fig. 3 Mean weekly infusion
duration with increasing flow
rates (safety analysis set). The
mean weekly infusion time for the
Manual Push Flow Rate Cohort at
the indicated flow rates. The
number of patients with infusion
duration data for each week (n) is
shown below each bar. Error bars
indicate SD. SD, standard
deviation

100

120
100
80
60
40
20
0

n=16

n=16

n=16

n=13

n=15

n=15

n=15

n=10

n=14

n=14

n=14

n=14

1

2

3

4

5

6

7

8

9

10

11

12

Week

J Clin Immunol (2021) 41:66–75
Table 2 Infusion compliance
(safety analysis set)

71

0.5 mL/min/site, N = 16

Flow rate

1 mL/min/site, N = 16

2 mL/min/site, N = 14

99.5 (10.1)
100.0 (82.9, 131.7)

93.7 (11.8)
99.8 (60.7, 100.5)

98.5 (3.5)
100.0 (90.0, 100.5)

2 (12.5)a

4 (25.0)a

0

14 (87.5)

12 (75.0)

14 (100.0)

Overall compliance (administered dose/planned dose, %)
Mean (SD)
Median (min, max)
Compliance level, n (%)
< 90%
≥ 90%
a

One patient had a compliance < 90% at 2 flow rates (0.5 mL/min and 1 mL/min)

N, total number of patients per infusion parameter level; n, number of patients; SD, standard deviation

24 to 80 mL, and median cumulative weekly IgPro20 doses
ranged from 63 to 211 mg/kg (Fig. 4). As planned, the median
(min, max) duration of exposure was 4.00 (2.9, 5.3) weeks at
the 0.5-mL/min rate, 4.00 (3.1, 4.6) weeks at the 1.0-mL/min
rate, and 4.22 (3.7, 4.7) weeks at the 2.0-mL/min rate.
Overall, including TEAEs occurring after non-response, 12
patients (75.0%) experienced 53 TEAEs across all infusion
flow rates, with a rate of 0.085 TEAEs per infusion. A total
of 33 TEAEs in 6 patients (37.5%) were considered treatmentrelated, corresponding to 0.053 related TEAEs per infusion.
TEAEs that occurred under forced upward titration conditions (before non-response) were characterized in more detail.
The frequency of TEAEs and the rate of TEAEs per infusion
were low and comparable between infusion parameter levels
(Table 3). Treatment-related TEAEs were experienced by 3
patients (18.8%), 5 patients (31.3%), and 3 patients (21.4%) at
the 0.5-, 1.0-, and 2.0-mL/min flow rates, respectively. Most
TEAEs were mild; 3 patients (21.4%) experienced 3 moderate
TEAEs at the 2.0-mL/min infusion level. As noted above,
only one patient had a serious TEAE (suicide attempt), which
was unrelated to treatment and led to study drug
discontinuation.
Across all flow rate levels, the most frequent TEAEs were
local reactions, all of which were mild. At the 0.5-mL/min
flow rate, 5 treatment-related local TEAEs occurred in 2

Serum IgG Trough Concentrations
The mean (SD) serum IgG trough level in patients at the end
of the study (9.58 [2.12] g/L; n = 15) was similar to the baseline IgG trough level in patients on day 1 of the study (9.36
[2.53] g/L; n = 16).

Discussion
Patients with PID and prior experience with manual push infusion had very high responder rates in this study at all flow
rate levels of IgPro20 tested, suggesting the feasibility of
IgPro20 manual push flow rates up to 2.0 mL/min.

90
80
Median weekly volume, mL

Fig. 4 Median cumulative
weekly IgPro20 volume and dose
administered per patient (safety
analysis set). The cumulative
median weekly volume (mL) and
dose (mg/kg) of IgPro20
administered per patient during
the study; each dot represents an
individual patient. Owing to
differences in patient body
weight, individual volumes
administered vary even if the dose
is the same, as volume depends on
body weight

patients (12.5%), for a rate of 0.023 treatment-related local
TEAEs per infusion. The 1.0-mL/min flow rate had the
highest frequency of treatment-related local TEAEs, with 17
events occurring in 4 patients (25.0%), for a rate of 0.082
treatment-related local TEAEs per infusion. Finally, 5
treatment-related local TEAEs occurred in 2 patients
(14.3%) at the 2.0-mL/min flow rate, resulting in a rate of
0.025 treatment-related local TEAEs per infusion. As there
were no severe local reactions, the tolerability was 100% for
each flow rate level. No deaths were reported in this study.

70
60
50
40
30
20
10
0
0

50

100

150

Median weekly dose, mg/kg

200

250
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Treatment-emergent adverse events under forced upward titration conditions
0.5 mL/min/site (N = 16; Inf = 220)

1 mL/min/site (N = 16; Inf = 208)

2 mL/min/site (N = 14; Inf = 198)

n (%)

E (rate)

n (%)

E (rate)

n (%)

E (rate)

Any TEAE

5 (31.3)

14 (0.064)

9 (56.3)

23 (0.111)

7 (50.0)

16 (0.081)

Treatment-related
Intensity of TEAEs
Mild
Moderate
Severe
Serious TEAEs
Treatment-related

3 (18.8)

9 (0.041)

5 (31.3)

18 (0.087)

3 (21.4)

6 (0.030)

5 (31.3)
0
0
0
0

14 (0.064)
0
0
0
0

8 (50.0)
0
1 (6.3)a
1 (6.3)a
0

22 (0.106)
0
1 (0.005)a
1 (0.005)a

7 (50.0)
3 (21.4)
0
0

13 (0.066)
3 (0.015)
0
0

0

0

0

Deaths
Study discontinuation due to TEAE
Treatment-related
Study drug withdrawal due to TEAE
Treatment-related

0
0
0
0
0

0
0
0
0
0

0
1 (6.3)a
0
1 (6.3)a
0

0
1 (0.005)a

0
0

0
0

0
1 (0.005)a

0
0

0
0

0

0

0

Local TEAEs
Treatment-related

3 (18.8)
2 (12.5)

6 (0.027)
5 (0.023)

4 (25.0)
4 (25.0)

17 (0.082)
17 (0.082)

2 (14.3)
2 (14.3)

5 (0.025)
5 (0.025)

Most common (> 1 event at any flow rate) TEAEs by preferred term
Injection site pain

1 (6.3)

4 (0.018)

2 (12.5)

4 (0.019)

1 (7.1)

1 (0.005)

Injection site bruising

0

0

1 (6.3)

2 (0.010)

1 (7.1)

3 (0.015)

Injection site swelling

1 (6.3)

1 (0.005)

1 (6.3)

3 (0.014)

1 (7.1)

1 (0.005)

Injection site erythema

0

0

1 (6.3)

3 (0.014)

0

0

0

0

1 (6.3)

2 (0.010)

0

0

Injection site discoloration
Injection site pruritus
Diarrhea

0

0

1 (6.3)

2 (0.010)

0

0

2 (12.5)

3 (0.014)

1 (6.3)

1 (0.005)

0

0

Nausea

2 (12.5)

3 (0.014)

0

0

0

0

Upper respiratory tract infection

0

0

0

0

2 (14.3)

2 (0.010)

Most common (> 1 event at any flow rate) treatment-related TEAEs by preferred term
Injection site pain

1 (6.3)

4 (0.018)

2 (12.5)

4 (0.019)

1 (7.1)

1 (0.005)

Injection site bruising

0

0

1 (6.3)

2 (0.010)

1 (7.1)

3 (0.015)

Injection site swelling

1 (6.3)

1 (0.005)

1 (6.3)

3 (0.014)

1 (7.1)

1 (0.005)

Injection site erythema

0

0

1 (6.3)

3 (0.014)

0

0

Injection site discoloration

0

0

1 (6.3)

2 (0.010)

0

0

Injection site pruritus

0

0

1 (6.3)

2 (0.010)

0

0

Diarrhea

1 (6.3)

2 (0.009)

1 (6.3)

1 (0.005)

0

0

Nausea

1 (6.3)

2 (0.009)

0

0

0

0

Rate = number of events/total number of infusions prior to patient’s start date of non-response
Excludes TEAEs occurring after non-response
E, number of events; Inf, infusions; n, number of patients; TEAE, treatment-emergent adverse event
a

One patient with a documented medical history of depression had a severe, unrelated serious TEAE (suicide attempt) that led to study discontinuation
after administering 5 of 8 planned infusions at the 1.0-mL/min rate

Importantly, no new safety signals were observed in the current study compared with previous studies [4, 19, 20, 27].
Overall, the manual push flow rates evaluated were well tolerated, with only mild local site reactions. Treatment-related
TEAE rates under forced upward titration conditions were low
(0.030–0.087 events per infusion), on the lower end of the

range of treatment-related TEAE rates observed across phase
III trials of IgPro20 (0.003–0.634 events per infusion) [24].
No increases in TEAEs or TEAE rate per infusion were observed with increasing flow rates.
To the best of our knowledge, this is the first prospective
clinical study to evaluate subcutaneous IgPro20 manual push
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infusion parameters, as most previous prospective studies of
IgPro20 have used infusion pumps [4, 27] or have not specifically assessed infusion flow rates [8]. The tolerability of
IgPro20 manual push flow rates of 0.5 to 2.0 mL/min in specific patient subgroups (e.g., young [≤ 17 years] and underweight [BMI ≤ 18 kg/m2] patients) is of particular interest,
since age and weight may impact tolerability. In this study,
only one adolescent patient (aged 17 years) was enrolled in the
Manual Push Flow Rate Cohort; therefore, no conclusion
could be drawn on the tolerability of higher manual push flow
rates in adolescent patients (aged 12–17 years). In general, the
clinical efficacy and safety of IgPro20 has been shown to be
comparable between pediatric, adolescent, and adult patients
[28]. However, a previous report suggested that SCIG administration via manual push is a preferred administration method
by parents of children aged < 2 years, as it allows for the
shortest infusion time [16]. The same study suggested that
children aged 2–10 years prefer pump-assisted infusions for
SCIG, due to fear of needles and distress over the appearance
of the subcutaneous bump [16]. Preference reportedly shifts
back to manual push infusions of SCIG during teenage years
[16]. Given that shorter infusion times and flexible dosing
may be preferred by pediatric and/or adolescent patients, further investigation of manual push flow rates up to 2.0 mL/min
for IgPro20 in these patient subgroups is warranted.
Furthermore, while one cannot rule out the possibility that
obese patients tolerate high flow rates better than patients with
normal or low BMI, both obese and non-obese patients
showed high responder rates across infusion flow rates in
the present study, with no meaningful differences in tolerability observed between these two subpopulations. The lowest
patient BMI in the Manual Push Cohort was 19.21 kg/m2;
therefore, the tolerability of the IgPro20 manual push infusion
flow rates tested here in underweight patients remains to be
determined. Patients administering IgPro20 via manual push
were required to maintain the same weekly frequency of infusions throughout the study but could, at study initiation,
choose a frequency to suit their personal needs (2–7 infusions
per week), which represents another advantage of the manual
push infusion approach [7, 12, 16].
The overall mean IgPro20 weekly dose in this study was
113–137 mg/kg, which is within the typical dose range reported for patients with PID in the USA (100–200 mg/kg per
week) [19, 22, 27]. Corresponding cumulative weekly volumes of IgPro20 ranged from 24 to 80 mL, with 8 of 16
patients infusing volumes ≥ 60 mL/week (Fig. 4), which demonstrates that even patients with relatively high SCIG volumes
can successfully and safely use manual push administration.
Throughout this study, serum IgG trough levels were maintained at similar or higher levels than those at study entry,
indicating that higher manual push flow rates do not affect
the treatment goal of maintaining minimum stable serum
IgG levels in patients with PID.
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As anticipated, IgPro20 manual push infusion time was
reduced with increasing flow rates. Specifically, there was a
4-fold reduction in infusion time from the 0.5-mL/min flow
rate to the 2.0-mL/min flow rate. While not all patients tolerated the highest flow rate, all patients tolerated a higher flow
rate than currently approved for pump-assisted infusions
(25 mL/h per injection site). Consequently, each patient found
the flow rate they were comfortable with and managed to
reduce the infusion time substantially. Based on the results
of this study, it is recommended that a manual push flow rate
of up to 2.0 mL/min per injection site be adopted for IgPro20
in treatment-experienced patients with PID, to allow patients
more options in selecting the flow rate with which they are
most comfortable.
There are some notable limitations to this study. First and
foremost, patients with PID were selected for inclusion in
the Manual Push Flow Rate Cohort based on previous experience with frequent manual push IgPro20 infusions at a
flow rate of approximately 0.5 mL/min. Therefore, these
patients may have been more likely to tolerate higher flow
rates, as they were already familiar and comfortable with the
manual push technique for IgPro20 infusions. This may
have also contributed to the low rates of treatment-related
TEAEs per infusion observed here. However, treatmentnaïve patients in the USA are advised to start Hizentra infusions with low volumes and flow rates (up to 15 mL and
15 mL/h per injection site for the first infusion) and increase
slowly based on tolerability [14]. Although the study
allowed for enrollment of patients aged ≤ 17 years as well
as patients who were underweight (BMI ≤ 18 kg/m2), only
one patient aged 17 years was enrolled in the Manual Push
Cohort, and no underweight patients were enrolled.
Therefore, the generalizability of the findings for the
Manual Push Cohort in this study are limited to adults (aged
≥ 18 to 65 years) and normal-weight or obese individuals
(BMI ≥ 19 kg/m2). Finally, while the proportion of patients
with bronchiectasis in this cohort (25%) compares well with
the average proportion among patients with CVID in
Europe (25%, range 0–66) [29], it is lower than the recently
reported global average for patients with CVID (34%; 95%
confidence interval: 30–38) [30]. Overall, the proportion of
patients with bronchiectasis among patients with PID depends on many factors and shows great regional variability
[31]. Due to the relatively low number of patients in this
study, a broad conclusion as to the reason for this apparent
discrepancy would not be meaningful. To better evaluate
the safety and tolerability of manual push administration
in a broader PID population, and possibly evaluate even
higher flow rates, larger studies would be beneficial.
In conclusion, the results presented here demonstrate that
manual push infusions of subcutaneous IgPro20 at flow rates
of 0.5–2.0 mL/min (30–120 mL/h) are feasible and well tolerated in treatment-experienced patients with PID. The
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manual push technique can reduce overall administration
time, thereby providing patients with more freedom and flexibility to individualize IgG replacement therapy.
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